Picture of Curatis Holding AG logo

CURN Curatis Holding AG Share Price

0.000.00%
ch flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m+33.58%
3m+135.02%
6m+98.63%
1yr+356.71%
Volume Change (%)
10d/3m-5.91%
Price vs... (%)
52w High-55.06%
50d MA+36.72%
200d MA+27.97%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-1533.3%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Curatis Holding AG EPS forecast chart

Profile Summary

Curatis Holding AG formerly Kinarus Therapeutics Holding AG is a Switzerland-based company that operates in specialty pharmaceutical and therapeutic drug industry. The Company conducts its work within clinical-stage area and focuses on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of diseases. This is done by distributing specialty pharmaceuticals throughout Switzerland, with aims to expanded to larger European markets such as Germany, France, United Kingdom as well as Italy. The drugs and treatments produced are primarily developed in order to treat rare diseases, often referred to as orphan diseases, which receive little funding, relative to more common disorders.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
April 8th, 1997
Public Since
October 18th, 1999
No. of Employees
15
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
ch flag iconSIX Swiss Exchange
Shares in Issue
4,810,544.25

CURN Share Price Performance

Upcoming Events for CURN

Similar to CURN

Picture of Cosmo Pharmaceuticals NV logo

Cosmo Pharmaceuticals NV

ch flag iconSIX Swiss Exchange

Picture of Dottikon Es Holding AG logo

Dottikon Es Holding AG

ch flag iconSIX Swiss Exchange

Picture of Galenica AG logo

Galenica AG

ch flag iconSIX Swiss Exchange

Picture of Novartis AG logo

Novartis AG

ch flag iconSIX Swiss Exchange

Picture of PolyPeptide AG logo

PolyPeptide AG

ch flag iconSIX Swiss Exchange

FAQ